TREMERA - BIO study

• Research type

  Research Study

• Full title

  Investigating IL-6 intracellular signalling and changes induced by Tocilizumab & Methotrexate Combination and Tocilizumab Monotherapy in Patients with Early Rheumatoid Arthritis: The ‘Tocilizumab REMission in Early RA’ BIOlogical (TREMERA-BIO) study\n

• IRAS ID

  235560

• Contact name

  Maya Buch

• Contact email

  m.buch@leeds.ac.uk

• Sponsor organisation

  The University of Leeds

• Duration of Study in the UK

  3 years, 0 months, 1 days

• Research summary

  This ethics is to provide on-going use and analysis of those biological and synovial biopsy tissue samples derived from the original TREMERA study - consent is already in place for future use within TREMERA-BIO.

• REC name

  South Central - Berkshire B Research Ethics Committee

• REC reference

  17/SC/0675

• Date of REC Opinion

  22 Dec 2017

• REC opinion

  Favourable Opinion